# Endocytic Pathways and Actin Remodeling Mediate Everolimus-Induced VE-Cadherin Disorganization and Barrier Dysfunction

**Authors:** Ken D. Brandon, Yoshi Chettri, Azkah Anjum, Kimberly M. Stroka

PMC · DOI: 10.1007/s12195-025-00881-y · Cellular and Molecular Bioengineering · 2025-12-03

## TL;DR

Everolimus disrupts blood vessel integrity by altering VE-cadherin and actin structures, with recovery partially dependent on the Golgi.

## Contribution

Identifies endocytic and Golgi pathways as key in everolimus-induced endothelial dysfunction.

## Key findings

- EVL reduces VE-cadherin continuity and increases punctate junctions in a time-dependent manner.
- Inhibiting endocytosis or lysosomal degradation preserves VE-cadherin, while Golgi disruption blocks recovery.
- EVL increases dextran permeability and decreases TEER, showing significant barrier disruption.

## Abstract

VE-cadherin is a key component of endothelial adherens junctions, and its disorganization contributes to vascular dysfunction. While rapamycin analogs like everolimus (EVL) are clinically linked to endothelial barrier dysfunction (EBD), the underlying molecular mechanisms remain poorly defined. This study investigates how EVL alters VE-cadherin organization, trafficking, cytoskeletal architecture, and barrier function in endothelial cells.

Human umbilical vein endothelial cells (HUVECs) were treated with 500 nM EVL for 4 or 24 h. Junctional VE-cadherin organization was quantified using confocal microscopy and the Junction Analyzer Program. Cytoskeletal changes were assessed via F-actin anisotropy, and pharmacologic inhibitors (chlorpromazine, chloroquine, and brefeldin A) were used to block clathrin-mediated endocytosis, lysosomal degradation, and Golgi trafficking, respectively. Barrier function was evaluated using TEER and 4 kDa FITC-dextran transwell assays.

EVL reduced continuous VE-cadherin and increased punctate junctions in a time-dependent but partially reversible manner. Inhibiting endocytosis or lysosomal degradation preserved VE-cadherin continuity, while Golgi disruption blocked recovery. EVL also increased F-actin anisotropy, reflecting enhanced stress-fiber alignment within individual cells, but transiently uncoupled intracellular actin organization from coordinated cytoskeletal alignment across the monolayer. Functionally, EVL decreased TEER and increased dextran permeability by 2.24–2.63-fold, indicating significant barrier disruption.

EVL compromises endothelial barrier integrity by promoting VE-cadherin internalization and lysosomal degradation, accompanied by cytoskeletal remodeling and a Golgi-dependent, partial restoration of junctional VE-cadherin. These findings highlight endocytic, degradative, and Golgi-mediated trafficking pathways as key modulators of EVL-induced endothelial barrier dysfunction and provide mechanistic insight into the vascular effects of rapalog-based mTOR inhibition.

The online version contains supplementary material available at 10.1007/s12195-025-00881-y.

## Linked entities

- **Proteins:** cdh5 (cadherin 5), Act5C (Actin 5C)
- **Chemicals:** everolimus (PubChem CID 6442177), chlorpromazine (PubChem CID 2726), chloroquine (PubChem CID 2719), brefeldin A (PubChem CID 5287620)
- **Species:** Homo sapiens (taxon 9606)

## Full-text entities

- **Genes:** CDH5 (cadherin 5) [NCBI Gene 1003] {aka 7B4, CD144}, MTOR (mechanistic target of rapamycin kinase) [NCBI Gene 2475] {aka FRAP, FRAP1, FRAP2, RAFT1, RAPT1, SKS}
- **Diseases:** vascular dysfunction (MESH:D002561)
- **Chemicals:** chlorpromazine (MESH:D002746), FITC-dextran (MESH:C015219), chloroquine (MESH:D002738), brefeldin A (MESH:D020126), dextran (MESH:D003911), EVL (MESH:D000068338), rapamycin (MESH:D020123)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12915895/full.md

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12915895/full.md

## References

1 references — full list in the complete paper: https://tomesphere.com/paper/PMC12915895/full.md

---
Source: https://tomesphere.com/paper/PMC12915895